Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Hovsepian

Cardiovascular Disease Alhambra, CA Medical Doctor

NPI 1689616153 CMS profile 30343

11 E Adams Ave, Alhambra, CA 91801

Open in the dashboard

General payments

$5,760

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Hovsepian of Alhambra, CA is reported in the CMS Open Payments database as having received $5,760 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $388 10
2024 General $427 12
2023 General $1,410 31
2022 General $2,397 38
2021 General $860 17
2020 General $124 6
2019 General $154 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Hovsepian
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Paul Hovsepian were reported at $388. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Paul Hovsepian Cardiovascular Disease median Middle half National median
2019 $154 $450 $127–$1,392 $163
2020 $124 $242 $77–$751 $114
2021 $860 $335 $101–$1,037 $132
2022 $2,397 $395 $121–$1,211 $149
2023 $1,410 $443 $136–$1,283 $160
2024 $427 $450 $136–$1,323 $164
2025 $388 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,471 53 payments
  2. Cardiva Medical, Inc. $490 4 payments
  3. Boston Scientific Corporation $309 4 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $179 8 payments
  5. Lilly USA, LLC $170 5 payments
  6. HeartFlow, Inc. $150 1 payment
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $149 9 payments
  8. Abbott Laboratories $146 2 payments
  9. Novartis Pharmaceuticals Corporation $137 6 payments
  10. Novo Nordisk Inc $68 3 payments
  11. Other $492 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,083 111 payments
  2. Travel and Lodging $677 8 payments
Products named General payments · program years 2019–2025
  1. Micra $2,208 34 payments
  2. LINQ II $784 8 payments
  3. Cardiva VASCADE MVP VVCS 6-12F $273 3 payments
  4. Reveal LINQ $218 7 payments
  5. Cardiva VASCADE 6/7F VCS $216 1 payment
  6. Kerendia $179 8 payments
  7. MOUNJARO $170 5 payments
  8. FFRct $150 1 payment
  9. LifeVest $149 9 payments
  10. TYRX $144 1 payment
  11. Other $1,580 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

259

Median for Cardiology: 2,533

Drug cost

$68,387

Median for Cardiology: $485,213

Branded share of claims

35.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 36 $34,518
Brilinta Ticagrelor Brand 24 $11,338
Entresto Sacubitril/Valsartan Brand 18 $10,861
Eliquis Apixaban Brand 14 $10,449
Metoprolol Succinate Generic 25 $670
Carvedilol Generic 32 $145
Amlodipine Besylate Generic 13 $67
Furosemide Generic 18 $64
Metoprolol Tartrate Generic 14 $61
Atorvastatin Calcium Generic 12 $60

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$241,792

Medicare's payments for the services billed

Medicare patients

700

Average age 80

Services billed

3,218

377 women, 323 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Ischemic heart disease 68%
Chronic kidney disease 64%
Arthritis 58%
Heart failure 56%
Alzheimer's or dementia 48%
COPD 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $38
$38 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $38
$38 18 —
MOUNJARO
  • Lilly USA, LLC $35
$35 — —
ZEPBOUND
  • Lilly USA, LLC $35
$35 — —
Ozempic
  • Novo Nordisk Inc $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record